INVESTORS & MEDIA

Press Releases


Press Releases

March 27, 2019
DURHAM, N.C. , March 27, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the pricing of its initial public offering of 7,900,000 shares of...
March 14, 2019
DURHAM, North Carolina, USA, March 14, 2019  – Precision BioSciences (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, has appointed Raymond Schinazi, PhD, Hon DSc to its board of directors. Dr....
March 9, 2019
DURHAM, North Carolina, USA, March 16, 2019  – Precision BioSciences (“Precision” or the “Company”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced that it has entered into an agreement for the issuance and sale of...